Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model

Introduction: In a 24-hour porcine model of liver injury, we showed that fibrinogen supplementation does not downregulate endogenous fibrinogen synthesis. Here we report data from the same study showing the impact of fibrinogen on coagulation variables. Materials and Methods: Coagulopathy was induced in 20 German land race pigs by hemodilution and blunt liver injury. Animals randomly received fibrinogen concentrate (100 mg/kg) or saline. Coagulation parameters were assessed and thromboelastometry (ROTEM) was performed. Results: Fibrinogen concentrate significantly reduced the prolongations of EXTEM clotting time, EXTEM clot formation time, and prothrombin time induced by hemodilution and liver injury. A decrease in clot strength was also ameliorated. Endogenous thrombin potential was significantly higher in the fibrinogen group than in the control group, 20 minutes (353 ± 24 vs 289 ± 22 nmol/L·min; P < .05) and 100 minutes (315 ± 40 vs 263 ± 38 nmol/L·min; P < .05) after the start of infusion. However, no significant between-group differences were seen in other thrombin generation parameters or in d-dimer or thrombin–antithrombin levels. Fibrinogen–platelet binding was reduced following liver injury, with no significant differences between groups. No significant between-group differences were observed in any parameter at ∼12 and ∼24 hours. Conclusion: This study suggests that, in trauma, fibrinogen supplementation may shorten some measurements of the speed of coagulation initiation and produce a short-lived increase in endogenous thrombin potential, potentially through increased clotting substrate availability. Approximately 12 and 24 hours after starting fibrinogen concentrate/saline infusion, all parameters measured in this study were comparable in the 2 study groups.

[1]  R. Rossaint,et al.  Fibrinogen Concentrate Does Not Suppress Endogenous Fibrinogen Synthesis in a 24-hour Porcine Trauma Model , 2014, Anesthesiology.

[2]  W. Voelckel,et al.  Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients , 2014, Critical Care.

[3]  H. Redl,et al.  Recovery of fibrinogen concentrate after intraosseous application is equivalent to the intravenous route in a porcine model of hemodilution , 2014, The journal of trauma and acute care surgery.

[4]  D. Fries,et al.  Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs , 2014, Transfusion.

[5]  P. Wouters,et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. , 2013, European journal of anaesthesiology.

[6]  J. Vincent,et al.  Management of bleeding and coagulopathy following major trauma: an updated European guideline , 2013, Critical Care.

[7]  W. Voelckel,et al.  Potential value of pharmacological protocols in trauma , 2013, Current opinion in anaesthesiology.

[8]  C. Solomon,et al.  Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery , 2013, British journal of anaesthesia.

[9]  S. Stanworth,et al.  The incidence and magnitude of fibrinolytic activation in trauma patients , 2013, Journal of thrombosis and haemostasis : JTH.

[10]  H. Wendel,et al.  Flow cytometry analysis of porcine platelets: Optimized methods for best results , 2012, Platelets.

[11]  A. Sauaia,et al.  Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. , 2012, Journal of the American College of Surgeons.

[12]  W. Voelckel,et al.  Early and individualized goal-directed therapy for trauma-induced coagulopathy , 2012, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[13]  B. Sørensen,et al.  Emerging treatment strategies for trauma‐induced coagulopathy , 2012, The British journal of surgery.

[14]  R. Davenport,et al.  Management of major trauma haemorrhage: treatment priorities and controversies , 2011, British journal of haematology.

[15]  P. Innerhofer,et al.  Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. , 2011, British journal of anaesthesia.

[16]  R. Rossaint,et al.  Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. , 2011, Blood.

[17]  S. Bélisle,et al.  Prevention and treatment of coagulopathy in patients receiving massive transfusions , 2011, Vox sanguinis.

[18]  S. Skrtic,et al.  Prophylactic Fibrinogen Infusion in Cardiac Surgery Patients: Effects on Biomarkers of Coagulation, Fibrinolysis, and Platelet Function , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[19]  W. Voelckel,et al.  Platelet function following trauma , 2011, Thrombosis and Haemostasis.

[20]  R. Rossaint,et al.  Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury , 2010, Critical care.

[21]  R. Rossaint,et al.  A New Model for Blunt Liver Injuries in the Swine , 2009, European Surgical Research.

[22]  S. Skrtic,et al.  Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery , 2009, Thrombosis and Haemostasis.

[23]  Kenichi A. Tanaka,et al.  Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. , 2009, British journal of anaesthesia.

[24]  A. Haverich,et al.  Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study , 2009, British journal of anaesthesia.

[25]  J. Ingerslev,et al.  Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial , 2009, Journal of thrombosis and haemostasis : JTH.

[26]  M. Dubick,et al.  Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. , 2008, The Journal of trauma.

[27]  M. Prins,et al.  Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory , 2008, Thrombosis and Haemostasis.

[28]  Kenichi A. Tanaka,et al.  Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P) , 2008, Anesthesia and analgesia.

[29]  W. Schobersberger,et al.  The Effect of Fibrinogen Substitution on Reversal of Dilutional Coagulopathy: An In Vitro Model , 2006, Anesthesia and analgesia.

[30]  W. Kreuz,et al.  Pharmacokinetic properties of a pasteurised fibrinogen concentrate. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[31]  D. S. Neblock,et al.  Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. , 1996, Blood.

[32]  E. Vahtera,et al.  Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell Concentrates , 1995, Anesthesia and analgesia.

[33]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[34]  C. Kolbitsch,et al.  Normal values for thrombelastography (ROTEM) and selected coagulation parameters in porcine blood. , 2006, Thrombosis research.